Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
Apoptosis · 2026
DOI: 10.1007/s10495-026-02275-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Apoptosis, 2026. Verfasst von Emirhan Harbi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Bahcesehir University, 34353, Istanbul, Turkey. emirhan.ha…. Hauptthemen laut MEDLINE: Glioblastoma, Vascular Endothelial Growth Factor A, Basic Helix-Loop-Helix Proteins, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bahcesehir University.
Abstract (Originalsprache)
Glioblastoma is the most aggressive and most common grade 4 tumor of the central nervous system (CNS). Despite standard treatments such as surgical resection and chemoradiotherapy, overall survival (OS) usually does not exceed 14–16 months in clinical trials, and no improvement in OS has been demonstrated even with the use of vascular endothelial growth factor A (VEGFA) inhibitors such as bevacizumab. In response to radiotherapy, hypoxia-inducible factor (HIF) stabilization leads to activation of alternative pro-angiogenic pathways, increasing VEGF expression and tumor angiogenesis. Several clinical trials evaluating HIF-2α inhibitors as monotherapy in the absence of concurrent VEGF inhibition, have similarly failed to demonstrate a significant improvement in OS outcomes. This review provides a perspective on the combined use of VEGF and HIF inhibitors, and provides an insight into future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Bahcesehir University, 34353, Istanbul, Turkey. emirhan.harbi@bahcesehir.edu.tr.
- Computational Biology and Molecular Simulations Laboratory (HITMER), Department of Biophysics, School of Medicine, Bahcesehir University, 34734, Istanbul, Turkey. emirhan.harbi@bahcesehir.edu.tr.
- Research Institute for Health Sciences and Technologies (SABITA), Cancer Research Center, Istanbul Medipol University, 34956, Istanbul, Turkey. emirhan.harbi@bahcesehir.edu.tr.
- Department of Clinical Oncology, Institute of Oncology, Istanbul University, 34093, Istanbul, Turkey. emirhan.harbi@bahcesehir.edu.tr.
- Biruni University Research Center (B@MER), Biruni University, 34015, Istanbul, Turkey. emirhan.harbi@bahcesehir.edu.tr.
- Research Institute for Health Sciences and Technologies (SABITA), Cancer Research Center, Istanbul Medipol University, 34956, Istanbul, Turkey.
ORCID-Profile: Emirhan Harbi
Förderung
- Bahcesehir University
Zitieren
APA
Harbi, E., Byrne, Y. Y., Bozbey, H. U., Tastekin, D., Oncul, O., Hosseiny, S., Yahya, D., Yildiz, O., Erdogan, M., Slocum, A. K., Mason, C. E., & Aschner, M. (2026). Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma. Apoptosis. https://doi.org/10.1007/s10495-026-02275-5
Vancouver
Harbi E, Byrne YY, Bozbey HU, Tastekin D, Oncul O, Hosseiny S, et al. Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma. Apoptosis. 2026. doi:10.1007/s10495-026-02275-5
BibTeX
@article{Harbi2026,
author = {Harbi, Emirhan and Byrne, Yasemin Yozgat and Bozbey, Hamza Ugur and Tastekin, Didem and Oncul, Oral and Hosseiny, Soha and Yahya, Duha and Yildiz, Ozcan and Erdogan, Murat and Slocum, Abdul Kadir and Mason, Christopher E and Aschner, Michael},
title = {Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma},
journal = {Apoptosis},
year = {2026},
doi = {10.1007/s10495-026-02275-5}
}
EUVIMED